Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	1.33B
Revenue (ttm)	733.13M
Net Income (ttm)	47.18M
Shares Out	n/a
EPS (ttm)	0.01
PE Ratio	28.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	853
Open	0.3180
Previous Close	0.3180
Day's Range	0.3180 - 0.3180
52-Week Range	0.1970 - 0.4820
Beta	n/a
RSI	59.50
Earnings Date	Mar 27, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 5,150
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.

Financial numbers in CNY